Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Feb;21(2):e14456.
doi: 10.1002/alz.14456. Epub 2025 Jan 9.

Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4-carrying women: An observational study

Ainara Jauregi-Zinkunegi  1 , Carey E Gleason  2   3   4 , Barbara Bendlin  3   5 , Ozioma Okonkwo  3   5 , Bruce P Hermann  6   7 , Kaj Blennow  8   9 , Henrik Zetterberg  3   8   9   10   11   12 , Eef Hogervorst  13 , Sterling C Johnson  3   4   5   6 , Rebecca Langhough  3   5   6 , Kimberly D Mueller  3   6   14 , Davide Bruno  1
Affiliations
Observational Study

Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4-carrying women: An observational study

Ainara Jauregi-Zinkunegi et al. Alzheimers Dement. 2025 Feb.

Abstract

Introduction: Menopausal hormone therapy (MHT), along with the apolipoprotein E (APOE) ε4 allele, has been suggested as a possible risk factor for Alzheimer's disease (AD). However, the relationship between MHT and cerebrospinal fluid (CSF) biomarkers is unknown: we investigated this association, and whether APOE ε4 carrier status moderates it.

Methods: In an observational study of 136 cognitively unimpaired female participants (Mage = 66.0; standard deviation = 6.3), we examined whether MHT use alone or in interaction with APOE ε4 carrier status was associated with CSF levels of phosphorylated tau (p-tau), amyloid beta (Aβ)40, Aβ42, p-tau/Aβ42, and Aβ42/40 ratios.

Results: Significant interactions were found between APOE ε4 and MHT use for CSF biomarkers. APOE ε4 carriers who were MHT users showed worse levels of CSF p-tau/Aβ42 and Aβ42/40 ratios than all other users and non-users.

Discussion: The presence of both APOE ε4 and MHT may be associated with elevated amyloid deposition and AD pathology in this sample of participants who demonstrated high familial AD risk.

Highlights: Significant interactions were found between apolipoprotein E (APOE) ε4 and menopausal hormone therapy (MHT) use for cerebrospinal fluid (CSF) phosphorylated tau (p-tau)/amyloid beta (Aβ)42 and Aβ42/40 ratios. APOE ε4 carriers who were MHT users showed worse levels of CSF biomarkers than non-users and non-carriers, both users and non-users. Younger age at MHT initiation was associated with worse levels of the p-tau/Aβ42 and Aβ42/40 ratios in carriers only. The presence of both APOE ε4 carriage and MHT use may be associated with elevated amyloid deposition and AD pathology. Further studies with larger sample sizes are necessary to confirm the differences observed in the current study.

Keywords: Alzheimer's disease; apolipoprotein E ε4 allele; biomarker; cerebrospinal fluid; hormone therapy; menopause.

PubMed Disclaimer

Conflict of interest statement

H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). No other author reports any conflicts of interest or disclosures. Author disclosures are available in the supporting information.

Figures

FIGURE 1
FIGURE 1
Estimated marginal means of CSF levels of the p‐tau/Aβ42 ratio (log10 transformed) by MHT use and APOE ε4 carrier status, controlling for the covariates, with 95% confidence interval. Estimated marginal means and CIs of CSF p‐tau/Aβ42 ratio in each group (back‐transformed): ε4−MHT− = 0.023, 95% CI: [0.015, 0.034]; ε4+MHT− = 0.025, 95% CI: [0.016, 0.040]; ε4−MHT+ = 0.020, 95% CI: [0.014, 0.030]; ε4+MHT+ = 0.036, 95% CI: [0.023, 0.055]. Post hoc pairwise group comparisons: ε4+MHT+ versus ε4−MHT+, adjusted P < 0.001; ε4+MHT+ versus ε4−MHT−, adjusted P = 0.003; ε4+MHT+ vs. ε4+MHT−, adjusted P = 0.069; ε4−MHT− versus ε4+MHT−, adjusted P = 0.541; ε4−MHT− versus ε4−MHT+, adjusted P = 0.357; ε4+MHT− versus ε4−MHT+, adjusted P = 0.226. Aβ, amyloid beta; APOE, apolipoprotein E; CI, confidence interval; CSF, cerebrospinal fluid; ε4−, non‐carriers; ε4+, carriers; MHT, menopausal hormone therapy; p‐tau, phosphorylated tau.
FIGURE 2
FIGURE 2
Estimated marginal means of CSF levels of the Aβ42/40 ratio (pg/mL) by MHT use and APOE ε4 carrier status, controlling for the covariates, with 95% confidence interval. Estimated marginal means and CIs of CSF Aβ42/40 ratio in each group: ε4−MHT− = 0.058, 95% CI: [0.045, 0.071]; ε4+MHT− = 0.057, 95% CI: [0.042, 0.072]; ε4−MHT+ = 0.063, 95% CI: [0.050, 0.076]; ε4+MHT+ = 0.045, 95% CI: [0.031, 0.059]. Post hoc pairwise group comparisons: ε4+MHT+ versus ε4−MHT+, adjusted P < 0.001; ε4+MHT+ versus ε4−MHT−, adjusted P = 0.006; ε4+MHT+ versus ε4+MHT−, adjusted P = 0.046; ε4−MHT− versus ε4+MHT−, adjusted P = 0.777; ε4−MHT− versus ε4−MHT+, adjusted P = 0.262; ε4+MHT− versus ε4−MHT+, adjusted P = 0.262. Aβ, amyloid beta; APOE, apolipoprotein E; CI, confidence interval; CSF, cerebrospinal fluid; ε4−, non‐carriers; ε4+, carriers; MHT, menopausal hormone therapy
FIGURE 3
FIGURE 3
Scatterplot of CSF levels of the p‐tau/Aβ42 ratio (log10 transformed, y axis) versus age at MHT initiation (x axis), by APOE ε4 carrier status. Regression lines and 95% confidence intervals by APOE ε4 carrier status, with age at MHT initiation as predictor, and controlling for the covariates. Aβ, amyloid beta; APOE, apolipoprotein E; CSF, cerebrospinal fluid; ε4−, non‐carriers; ε4+, carriers; MHT, menopausal hormone therapy; p‐tau, phosphorylated tau
FIGURE 4
FIGURE 4
Scatterplot of CSF levels of the Aβ42/40 ratio (untransformed, y axis) versus age at MHT initiation (x axis), by APOE ε4 carrier status. Regression lines and 95% confidence intervals by APOE ε4 carrier status, with age at MHT initiation as predictor, and controlling for the covariates. Aβ, amyloid beta; APOE, apolipoprotein E; CSF, cerebrospinal fluid; ε4−, non‐carriers; ε4+, carriers; MHT, menopausal hormone therapy.∖
See this image and copyright information in PMC

References

    1. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332‐384. doi: 10.1016/j.jalz.2015.02.003 - DOI - PubMed
    1. Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105‐e125. doi: 10.1016/s2468-2667(21)00249-8 - DOI - PMC - PubMed
    1. Fisher DW, Bennett DA, Dong H. Sexual dimorphism in predisposition to Alzheimer's disease. Neurobiol Aging. 2018;70:308‐324. doi: 10.1016/j.neurobiolaging.2018.04.004 - DOI - PMC - PubMed
    1. Zhou H, Yu Z, Luo L, Xie F, Wang Y, Wan Z. The effect of hormone replacement therapy on cognitive function in healthy postmenopausal women: a meta‐analysis of 23 randomized controlled trials. Psychogeriatrics. 2021;21(6):926‐938. doi: 10.1111/psyg.12768 - DOI - PubMed
    1. Hogervorst E, Temple S, O'Donnell E. Sex differences in dementia. In: Sex Differences in Brain Function and Dysfunction. Springer Nature; 2023:309‐331. - PubMed

Publication types